Skip to main content
Sign In
 

Program Meeting Schedule

​Presented by the Division of Pulmonary Sciences and Critical Care Medicine and the Aspen Lung Conference


THOMAS L. PETTY

ASPEN LUNG CONFERENCE

62nd Annual Meeting

"Exploring New Therapeutic Pathways in Pulmonary Hypertension: Metabolism, Proliferation, and Personalized Medicine”

June 5-8, 2019​


 

5:00-7:00 PM

Evening Registration Reception

Gant Conference Center​​


 

8:00-8:20 AM

Welcome/Introduction

M. Patricia George, M.D., Chair

Brian Graham, M.D., Chair​


8:20-8:30 AM

The Thomas L. Petty Aspen Lung Conference:  A Historical Perspective

Dennis E. Doherty, M.D., FCCP /Professor of Medicine/University of Kentucky

Secretary/Treasurer, National Lung Health Education Program


Cellular Metabolism: Moderators – Irina Petrache, M.D. and Adela Cota-Gomez, Ph.D.

8:30-9:05 AM

MARVIN I. SCHWARZ LECTURE

ALTERED METABOLISM IN PAECS AND THE RV

Serpil C. Erzurum, M.D. Chair, Lerner Research Institute The Alfred Lerner Memorial Chair in Innovative Biomedical Research

Cleveland Clinic Foundation Cleveland, Ohio


9:05-9:30 AM

Discussion


9:30-9:45 AM

RIGHT VENTRICULAR FIBROSIS IN PULMONARY HYPERTENSION IS MEDIATED BY ACh/nAChR SIGNALING.

A. Vang1, J.H. Siamwala1, N.R. Kue1, T.J. Mancini1, D.J. McCullough2, A. Allawzi3, R. Clements1, Gaurav Choudhary1,4*, 1Vascular Research Laboratory, Providence VA Medical Center, Providence, RI; 2Department of Anatomical Sciences, The Edward Via College of Osteopathic Medicine, Auburn, AL; 3Pediatrics - CVP, University of Colorado, Denver, Aurora, CO; 4Department of Medicine, Alpert Medical School of Brown University, Providence, RI.


9:45-10:00 AM

RIGHT VENTRICULAR MITOCHONDRIAL BIOENERGETICS AND METABOLIC MODULATION IN A MODEL OF MALADAPTATIVE REMODELING TO PULMONARY ARTERIAL HYPERTENSION

Virgilio J Cadete1,2*, A. Cuillerier2,3, Y. Deng1, K. Rowe1, Y. Burelle2,3, D.J. Stewart1,2, 1Sinclair Centre for Regenerative Medicine, Ottawa Hospital Research Institute, Ottawa, Canada; 2Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Canada; 3Interdisciplinary School of Health Sciences, Faculty of Health Sciences, University of Ottawa, Ottawa, Canada.


10:00-10:30 AM

Coffee Break (Refreshments for conference participants only)


10:30-11:05 AM​   

STATE OF THE ART

IMMUNOLOGIC AND METABOLIC ALTERATIONS IN A NONHUMAN PRIMATE MODEL OF PULMONARY HYPERTENSION

Karen A. Norris, Ph.D. 

University of Georgia


11:05-11:30 AM

Discussion


11:30-11:45 AM   

ENDOTHELIAL INFLAMMATORY SIGNALING SUPPRESSES MDSC-MEDIATED PULMONARY VASCULAR REMODELING

Andrew J. Bryant1*, C. Fu1, Y. Lu1, M.A. Williams1, M.L. Brantly1, E.W. Scott2, Ph.D., 1Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, College of Medicine, University of Florida, Gainesville, FL; 2Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL.


11:45-12:00 Noon

IMMUNOGLOBULIN-(G)-TRIGGERED ACTIVATION OF THE COMPLEMENT CASCADE REGULATES PRO-INFLAMMATORY PROCESSES IN PULMONARY HYPERTENSION

Maria G Frid*, B.A. McKeon, M. Li, H. Zhang, S. Kumar, M.A. Fini, T. Sullivan, J. Laskowski, C.-J. Hu, J.M. Thurman, K.R. Stenmark, University Colorado Denver, Anschutz Medical Campus, Pediatric Critical Care, Aurora, CO.


12:00-1:30 PM​

Lunch (not provided by conference)


Cellular Metabolism: Moderators – Darlene Kim, M.D. and Rubin Tuder, M.D.

1:30-2:05 PM

STATE OF THE ART

CROSSTALK BETWEEN AUTOPHAGIC METABOLISM AND ANGIOCRINE SIGNALING IN PULMONARY ARTERIAL HYPERTENSION

Augustine M.K. Choi, M.D. Weill Cornell Medicine


2:05-2:30 PM

Discussion


2:30-2:45 PM

SEVERE PULMONARY ARTERIAL HYPERTENSION AND MICROVASCULATURE LOSS IN THE RAT SU5416-HYPOXIA MODEL IS ASSOCIATED WITH PROTRACTED ENDOTHELIAL CELL APOPTOSIS: A SELF-SUSTAINING CYCLE DRIVEN BY HEMODYNAMIC STRESS?

Y. Deng1, Ketul R. Chaudhary1,2*, A. Yang1, K.R. Rowe1, D.J. Stewart1,2, 1Regenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada; 2Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.


2:45-3:00 PM

PRO-SURVIVAL ADAPTATION OF PULMONARY VASCULATURE MEDIATED BY SPHINGOLIPIDS FOLLOWING CIGARETTE SMOKE EXPOSURE OR HYPOXIA

Kelly S. Schweitzer1*, T. Lahm2*, K. Goel3, A. Scruggs1, D. Cao1, E. Beatman1, E.V. Berdyshev1, M.B. Brown4, W. Janssen1, 3, I. Petrache1,3, 1National Jewish Health, Denver, CO; 2Indiana University and VAMC, Indianapolis, IN; 3University of Colorado, Aurora, Colorado; 4University of Washington, Seattle, WA.


3:00-3:30 PM

Break (Refreshments for conference participants only)


3:30-4:05 PM

ROGER S. MITCHELL LECTURE

METABOLISM AS A THERAPEUTIC TARGET INPULMONARY HYPERTENSION AND THE RV

Anna R. Hemnes, M.D.

Vanderbilt University Medical Center


4:05-4:30 PM​

Discussion


4:30-4:45 PM

TREATMENT WITH TREPROSTINIL AND METFORMIN NORMALIZES HYPERGLYCEMIA AND IMPROVES CARDIAC FUNCTION IN PRE-CLINICAL MODEL OF PULMONARY HYPERTENSION ASSOCIATED WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HFpEF)

L. Wang1, T. Satoh1, J. Baust1, J. Hu1, A. Mora1,2, M. Gladwin1,2, Yen-Chun Lai3*, 1Pittsburgh Heart, Lung, Blood and Vascular Medicine Institute, University of Pittsburgh; 2Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh; 3Division of Pulmonary, Critical Care, Sleep and Occupational Medicine, Indiana University School of Medicine.


4:45-5:00 PM

AN IMPLANTED MECHANICAL DEVICE IMPROVES PULMONARY ARTERY COMPLIANCE AND REDUCES PULMONARY ARTERY ELESTANCE

Marc Pritzker1*, J. Scandura2, K. Vollmer2, J. Gainor2, I. Lang3, 1Cardiology, University of Minnesota, Minneapolis, MN; 2ARIA Cardiovascular, Minneapolis, MN, 3Cardiology, Medical University of Vienna, Vienna Austria.


5:00-7:00 PM

POSTER VIEWING --- SOCIAL HOUR


 
​​​​​

Hypoxia Signaling: Moderator – Jeffrey Kern, M.D. and Eva Grayck, M.D.

8:00-8:35 AM

GILES F. FILLEY LECTURE 

HYPOXIA SIGNALING IN CANCER

M. Celeste Simon, Ph.D.

Philadelphia, Pennsylvania​


8:35-9:00 AM

Discussion


9:00-9:15 AM

MMP-8 DEFICIENCY PROMOTES VASCULAR REMODELING THROUGH ENHANCED INTEGRIN BETA-3 SIGNALING

Paul B. Dieffenbach*, R. Rehman, C.M. Haeger, A.M. Corcoran, A.M.F. Coronata, F. Polvorino, C.A. Owen, L.E. Fredenburgh, Brigham and Women’s Hospital, Boston, MA.


9:15-9:30 AM

DOWNREGULATION OF IRS2 EXAGGERATES PULMONARY VASCULAR REMODELING AND RIGHT VENTRICULAR HYPERTROPHY UNDER HYPOXIC CONDITIONS

Kazuyo Yamaji-Kegan*, H. Huang, Department of Anesthesiology and Critical Care Medicine, The Johns Hopkins Medical Institutions, Baltimore, MD.


9:30-10:00 AM

Coffee Break

MEET THE PROFESSOR SESSION (by Registration table)


10:00-10:35 AM

STATE OF THE ART

HYPOXIA SIGNALING IN PULMONARY HYPERTENSION​

Larissa A. Shimoda, M.D., Ph.D.

Johns Hopkins School of Medicine


10:35-11:00 AM

Discussion


11:00-11:15 AM

SELECTIVE DEPLETION OF VASCULAR EC-SOD REPROGRAMS INTERSTITIAL MACROPHAGES IN RESPONSE TO HYPOXIA

Ayed Allawzi1*, I. McDermott1, S. Pugliese2, K. Elkasmi1, K. Stenmark1, E. Nozik-Grayck1, 1Cardiovascular Pulmonary Research Laboratories, Departments of Pediatrics and Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO; 2Paul F. Harron Jr. Lung Center, Perlman School of Medicine, University of Pennsylvania, Philadelphia, PA.


11:15-11:30 AM

HYPERACTIVATION OF HYALURONAN SYNTHESIS DRIVES PROLIFERATIVE METABOLISM IN PULMONARY HYPERTENSION

Victor Tseng1,2*, J. Kleinhenz2, E. Nozik-Grayck3; C. M. Hart1,2, 1Emory University Pulmonary, Allergy, Critical Care, and Sleep Medicine; 2Atlanta VA Medical Center; 3Cardiovascular and Pulmonary Research, University of Colorado, Aurora, CO.


12:00-3:00 PM

Picnic – T Lazy 7

The Ranch (for conference participants and their families)


​​

Aberrant Proliferation: Sonia Flores, Ph.D. and Kurt Stenmark, M.D.

8:00-8:35 AM

PARKER B. FRANCIS LECTURESHIP

ANGIOGENESIS REVISITED: ROLE AND (THERAPEUTIC) IMPLICATIONS OF ENDOTHELIAL METABOLISM

Peter Carmeliet, M.D., Ph.D.

Campus Gasthuisberg


8:35-9:00 AM

Discussion


9:00-9:15 AM

WNT SIGNALING REGULATES ANGIOGENESIS AND REMODELING DURING CHRONIC LUNG DISEASE WITH ASSOCIATED PULMONARY HYPERTENSION

Susan M. Majka*1, K.Y. Tao2, J.A. Kropski2, B.W. Richmond2, M.M. Taketo3, R.F. Foronjy4, 1National Jewish Health, Denver CO; 2Vanderbilt University and Medical Center, Nashville, TN; 3Kyoto University, Kyoto, Japan; 4SUNY Downstate, Brooklyn, NY.


9:15-9:30 AM

PI3K/AKT-INDUCED JNK SUPPRESSION CONTRIBUTES TO APOPTOSIS RESISTANCE IN BMPR2-SILENCED PULMONARY ARTERY ENDOTHELIAL CELLS

Keytam S. Awad*, S. Wang, J.M. Elinoff, R.L. Danner, CCMD, Clinical Center, National Institutes of Health, Bethesda, MD.


9:30-10:00 AM

Coffee Break

MEET THE PROFESSOR SESSION (by Registration table)


10:00-10:35 AM

REUBEN M. CHERNIACK LECTURE

THE PIVOTAL ROLE OF BMPR2 IN PREVENTING PULMONARY HYPERTENSION​

Marlene Rabinovitch, M.D. 

Stanford University School of Medicine


10:35-11:00 AM

Discussion


11:00-11:15AM

BONE MORPHOGENETIC PROTEIN RECEPTOR 2 (Bmpr2) MUTATIONS FACILITATE THE DEVELOPMENT OF A PROLIFERATIVE INFLAMMATORY ENDOTHELIAL PHENOTYPE IN PULMONARY HYPERTENSION​

Wen Tian1,2,*, X. Jiang1,2, Y.K. Sung1,2, E. Shuffle1,2, P. Kao2, A.B. Tu1,2, P. Maguire2, P. Zhang1,2, P. Dorfmüller3,4,5, J. Chappell2, P. Dahms1,2, A. Cao2, L. Wang2, S. Pasupneti1,2, G. Peng6, H. Chaib2, R. Zamanian2, M. Peters-Golden7, M.P. Snyder2, N.F. Voelkel8, M. Humbert3,4,9, M. Rabinovitch2, M.R. Nicolls1,2, 1VA Palo Alto Health Care System, Palo Alto, CA; 2Stanford University School of Medicine, Stanford, CA; 3Faculté de Médecine, Université Paris-Sud and Université Paris-Saclay, Le Kremlin-Bicêtre, France; 4INSERM UMR_S 999, Le Plessis-Robinson, France; 5Pathology Department, Hôpital Marie Lannelongue, Le Plessis-Robinson, Paris, France; 6State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China; 7University of Michigan Health System, Ann Arbor, MI; 8Free University Medical Center Amsterdam, the Netherlands; 9AP-HP, Service de Pneumologie, Centre de Référence de l’Hypertension Pulmonaire Sévère, DHU Thorax Innovation, Hôpital de Bicêtre, Le Kremlin-Bicêtre, France.


11:15-11:30 AM

SELECTIVE ACTIVATION OF ESTROGEN RECEPTOR α STIMULATES PULMONARY VASCULAR HOMEOSTATIC REGULATOR APELIN IN PULMONARY ARTERY ENDOTHELIAL CELLS (PAECS) FROM PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH)

Andrea Frump1*, B. Yakubov1, M. Albrecht1, S. Comhair2, D.T. Martinez3, N. Chesler3, T. Lahm1,4, 1Department of Medicine, Indiana University School of Medicine, Indianapolis, IN; 2Cleveland Clinic Lerner Research Institute, Cleveland, OH; 3Department of Biomedical Engineering, University of Wisconsin-Madison, Madison, Wisconsin; 4Richard L. Roudebush VA Medical Center, Indianapolis, IN.


11:30-1:30 PM​

Lunch (lunch not provided by conference)


Aberrant Proliferation: Susan Majka, Ph.D. and David Badesch, M.D.

1:30-2:05 PM

STATE OF THE ART

TRANSCRIPTION FACTOR REGULATION OF PULMONARY HYPERTENSION AND CANCER

Soni Savai Pullamsetti, Ph.D.

University of Giessen, Germany


2:05-2:30 PM

Discussion


2:30-2:45 PM

STIFFNESS-INDUCED TSC2 DEFICIENCY PROMOTES YAP/MTOR ACTIVATION, VASCULAR SMOOTH MUSCLE REMODELING AND PULMONARY HYPERTENSION​

Yuanjun Shen*, A. Pena, D.A. Goncharov, J. Baust, B.A.I. Chavez, A. Ray, A. Rode, S. Chan, B. Chang, A.L. Mora, T.V. Kudryashova, E.A. Goncharova, Vascular Medicine Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA.


2:45-3:00 PM

DEFICIENCY OF THE DEUBIQUITINASE, UCHL1, ATTENUATES PULMONARY HYPERTENSION

A. Gupta1, S.A. Morrisroe2, S. Sangam1,2, H. Tang3, G. Gupta1, S. Desai1, R. Rafikov1, O. Rafikova1, B. Mathew4, B. Larsen5, N. Andrew-Warfel1, L. Hecker1, S. Mitra6, S.M. Black1, J.X-J Yuan7, J. Jacobson3, J.G.N. Garcia1, Ankit A. Desai MD2*, 1Department of Medicine and Arizona Health Sciences Center, University of Arizona, Tucson, AZ; 2Department of Medicine, Indiana University, Indianapolis, IN; 3Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China; 4Department of Medicine, University of Illinois, Chicago, IL; 5Department of Pathology, May Clinic, Scottsdale, AZ; 6Department of Obstetrics and Gynecology, Indiana University, Indianapolis, IN; 7Department of Physiology, University of California-San Diego (UCSD), San Diego, CA.


3:00-3:30 PM

Break (Refreshments for conference participants only)


3:30-4:05 PM

STATE OF THE ART

NOVEL TREATMENT TARGETS IN PULMONARY HYPERTENSION

Steven M. Kawut, M.D.

University of Pennsylvania, Perelman School of Medicine


4:05-4:30 PM

Discussion


4:30-4:45 PM

THE ROLE OF FATTY ACID OXIDATION IN THE PATHOGENESIS OF PULMONARY HYPERTENSION

Michael H. Lee*, A. Gandjeva, D. Hernandez-Saavedra, L. Sanders, R. Kumar, C. Mickael, B.B. Graham, R.M. Tuder, Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado School of Medicine, Aurora, CO.


4:45-5:00 PM

MESENCHYMAL STEM CELLS (hMSC) EXOSOMES COUPLE THE RV/PA DURING PULMONARY FIBROSIS (PF)

J. Njah1, A. Marrocco1,, A. Detwiler1, J. Milosevic1, T. Beckman2, B. Rivera-Lebron2, M. Simon2, M. Rojas2, A. Mora2, D. Riches3, Luis A. Ortiz1,2*, 1Department of EOH; 2Medicine at the University of Pittsburgh; 3National Jewish Health, Denver, CO.


5:00-7:00 PM

POSTER VIEWING – Wine and Cheese Reception


 

Personalized Medicine: Moderators – Todd Bull, M.D. and Laurie Carr, M.D.

​8:00-8:35 AM

THOMAS L. PETTY LECTURE

BRIDGING GENES TO PHENOTYPE IN PULMONARY HYPERTENSION

Mark W. Geraci, M.D.

Indiana University School of Medicine​


8:35-9:00 AM

Discussion


9:00-9:15 AM

A PRELIMINARY FORAY of PROTEOMIC CLUSTERING IN PVDOMICS

Anna R. Hemnes, Evelyn M. Horn*, E.B. Rosenzweig, J. Leopold, G. Grunig, B. Willard, B. Hu, J. Barnard, and the PVDOMICS Study Group, Vanderbilt University, Weill Cornell, Columbia University, Brigham and Women’s, New York University School of Medicine, Cleveland Clinic.


9:15-9:30 AM

SINGLE CELL RNA SEQUENCING REVEALS EMERGENCE OF MULTIPLE ALVEOLAR MACROPHAGE SUBPOPULATIONS WITH DISTINCT TRANSCRIPTIONAL RECONFIGURATIONS IN SCHISTOSOMIASIS AND HYPOXIA EXPOSED MICE

Nzali Campbell*, C. Mickael, R. Kumar, M. Frid, K. Stenmark, B. Graham, School of Medicine, Anschutz Medical Campus, University of Colorado, Denver, CO.


9:30-10:00 AM

Coffee Break (Refreshments for conference participants only)


10:00-10:35 AM

THOMAS A. NEFF LECTURE

FOUR DECADES OF PERSONALIZED MEDICINE IN BREAST CANCER: LESSONS FOR DRUG DEVELOPMENT IN PULMONARY HYPERTENSION

Tatiana M. Prowell, M.D.

Johns Hopkins


10:35-11:00 AM

Discussion


11:00-11:15 AM

PERSONALIZING 6MW BY INCORPORATING HEART RATE ‘EXPENDITURE’

Daniel Lachant*, A. Light, R.J. White, University of Rochester Medical Center, Rochester, MN.


11:15-11:30 AM

MESENCHYMAL STEM CELL EXTRACELLULAR VESICLES INCREASE RECRUITMENT OF ALTERNATIVELY ACTIVATED MACROPHAGE TO LUNG AND REVERSE SUGEN/HYPOXIA-INDUCED PULMONARY HYPERTENSION IN RATS

James R. Klinger*, M. Pierra, M. Deltatto, M. Dooner, T. Borgovan, L. Goldberg, J.M. Aliotta, C.E. Ventetuolo, P.J. Quesenberry, O.D. Liang, Divisions of Pulmonary and Critical Care Medicine and Hematology/Oncology, Center for Stem Cell Biology, Rhode Island Hospital, Albert School of Medicine, Brown University, Providence, RI.


11:30-12:30 PM

CONFERENCE SUMMARY

Mark T. Gladwin, M.D. 

University of Pittsburgh​


12:30-1:00 PM

Discussion and Adjourn


 

POSTER VIEWING - SOCIAL HOUR
Wednesday, June 5, 2019
5:00-7:00 PM


 

POSTERS

PLATELET DEPLETION PREVENTS HYPOXIA-INDUCED PULMONARY VASCULAR PROLIFERATION AND INFLAMMATION IN MICE. Cassidy Delaney*, P. Davizon-Castillo, A. Allawzi, S. Fisher, J. Di Paola, K. Stenmark, E. Nozik-Grayzk, Pediatrics, University of Colorado , Denver, CO.

BONE MARROW DERIVED INTERSTITIAL MACROPHAGES CONTRIBUTES TO HYPOXIA-INDUCED PULMONARY HYPERTENSION. Rahul Kumar1*, C. Mickael1, B. Kassa1, L. Sanders1, D.E. Koyanagi1, S. Kumar2, W.J. Janssen3, K.R. Stenmark2, R.M. Tuder1, B.B. Graham1, 1Program in Translational Lung Research, Department of Medicine, University of Colorado, Anschutz Medical Campus, Aurora, CO; 2Department of Pediatrics and Medicine, Cardiovascular Pulmonary Research Laboratory, University of Colorado, Anschutz Medical Campus, Aurora, CO; 3Department of Medicine, National Jewish Health, Denver, CO.

CHITINASE 3-LIKE-1 CONTRIBUTES TO THE DEVELOPMENT OF RIGHT VENTRICULAR HYPERTROPHY AND PULMONARY VASCULAR REMODELING. X. Sun1, D. Yang1, C.E. Ventetuolo2, J. Braza3, J. Aliotta2, D. Banerjee2, M. Pereira2, E. Harrington3, S. Rounds3, C.G. Lee1, J.A Elias1,2, J.R. Klinger2, Yang Zhou1*, 1 Department of Molecular Microbiology and Immunology, Brown University, Providence, RI; 2Alpert Medical School of Brown University/Rhode Island Hospital, Providence, RI; 3Providence VA Medical Center, Providence, RI

GLUCOSE-6-PHOSPHATASE CATALYTIC SUBUNIT 3 (G6PC3) GENE SILENCING RESULTS IN A HYPER-PROLIFERATIVE PULMONARY ARTERY ENDOTHELIAL CELL PHENOTYPE. Li-Yuan Chen1*, E.J. Dougherty1, J.Y. Chou2, R.L. Danner1, J.M. Elinoff1, 1Critical Care Medicine Department, Clinical Center; 2Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD.

INFLAMMATORY PULMONARY VASCULAR DISEASE DUE TO SCHISTOSOMA JAPONICUM. Biruk Kassa*, R. Kumar, C. Mickael, L. Sanders, D. Koyanagi, B. Graham, Program in Translational Lung Research, University of Colorado, Denver, CO.

PROLIFERATION, APOPTOSIS RESISTANCE AND AKT ACTIVATION IN PHD2-SILENCED, PSEUDOHYPOXIC PULMONARY MICROVASCULAR ENDOTHELIAL CELLS. Shuibang Wang*, K.S. Awad, C.L. Wang, J.M. Elinoff , R.L. Danner, Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD.

ANALYSIS OF ALTERATIONS TO THE EXTRACELLULAR MATRIX IN PULMONARY HYPERTENSION USING PROTEOMICS. Jason S. Williams1*, M. Floren2, K.C. Hansen1, L.R. Schmitt1, K.R. Stenmark2, Department of Biochemistry and Molecular Genetics and Biological Mass Spectrometry Shared Resource; 2Cardiovascular Pulmonary Research Laboratories, Departments of Pediatrics and Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO.

RANOLAZINE BLUNTS DEVELOPMENT OF SPONTANEOUS PULMONARY HYPERTENSION IN IL-13 TRANSGENIC MICE. Sharon Rounds1*, M. Mundy1, A. Vang1, G. Choudhary1, Q. Lu1, J.A. Elias2, C. G. Lee2, W.-K. Cho1, 1Vascular Research Laboratory, Providence VA Medical Center, Department of Medicine; 2Department of Molecular Microbiology and Immunology, Warren Alpert Medical School of Brown University, Providence, RI.

DEVELOPMENTAL CARDIOPULMONARY ADAPTATION TO CHRONIC HYPOXIA LEADS TO EXTREME TRANSCRIPTOMIC MODIFICATIONS. Sheila Krishnan*, R.S. Stearman, E.A. Mickler, B.E. Hickey, M.W. Geraci, T. Lahm, R.S. Tepper, Indiana University School of Medicine, Department of Medicine, Indianapolis, IN.

QUANTIFICATION OF RIGHT VENTRICULAR MACROPHAGES IN TWO MURINE MODELS OF PULMONARY HYPERTENSION. Sue Gu*, C. Mickael, R. Kumar, L.Sanders, B. Kassa, B. Graham, Program in Translational Lung Research, Department of Medicine, University of Colorado Denver, Aurora, CO.

IMMUNOSUPPRESSIVE TREATMENT OF PAH. Marc Pritzker*, Cardiovascular Medicine and Surgery, University of Minnesota, Minneapolis, MN.

RELM REGULATES DAMP SIGNALING IN THE PATHOGENESIS OF PH-ASSOCIATED RIGHR VENTRICULAR DYSFUNCTION. Qing Lin*, X. Yang, W.D. Gao, J. Skinner, R. Johns, Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.

CHRONIC NICOTINE INHALATION PROMOTES THE DEVELOPMENT OF PULMONARY HYPERTENSION. J.M. Oakes1, C.S. Pearson1, J. Xu2, E. Lazartigues2, J.D. Gardner1, Xinping Yue1*, 1Departments of Physiology; 2Department of Pharmacology, Louisiana State University Health Sciences Center, New Orleans, LA.

MULTI-MODAL SHORT CHAIN FATTY ACID, BUTYRATE, IS THERAPEUTIC IN PULMONARY HYPERTENSION. D. Strassheim1, V. Karoor1, T. Sullivan1, P. Paucek2, A. Kovacs-Kasa3, A. Verin3, K. Stenmark1,4, Evgenia Gerasimovskaya4*, Departments of Medicine1, Neurology2, and Pediatrics4, University of Colorado Denver, Aurora, CO; 3Augusta University Vascular Biology Center, Augusta, GA.

THE BALANCE OF LUNG MICROVASCULAR INJURY AND REPAIR DETERMINED THE DEVELOPMENT OF A PULMONARY ARTERIAL HYPERTENSION IN A MURINE MODEL OF DIPHTHERIA TOXIN-MEDIATED ENDOTHELIAL CELL ABLATION. Rafael Soares Godoy1*, M. Taha1,2, Y. Deng1, K. Rowe1, D.J. Stewart1,2,1Sinclair Center for Regenerative Medicine, Ottawa Hospital Research Institute, Canada; 2University of Ottawa, Faculty of Medicine, Ottawa, Canada.

SUPEROXIDE IN PATIENTS UNDERGOING RIGHT HEART CATHETERIZATION. Tammy Wichman1*, M. Sanchez1, A. Thompson1, C. Wichman2, M. Zimmerman3, University of Nebraska Medical Center; 1Department of Internal Medicine Pulmonary Critical Care; 2Department of Biostatistics, 3Department of Physiology, Omaha, NE.

PULMONARY ADVENTITIAL FIBROBLASTS REGULATE MACROPHAGE TRANSCRIPTIONAL AND METABOLIC PROGRAMS IN PULMONARY HYPERTENSION. Min Li1*, S. Riddle1, S. Kumar1, K.C. El Kasmi1, A. D’alessandro3, D. Champagne3, H. Zhang1, A. Laux2, B.A. McKeon1, M.G. Frid1, D. Brown1, C.-J. Hu2, K.R. Stenmark1. 1Cardiovascular Pulmonary Research Laboratories, Departments of Pediatrics and Medicine; 2Department of Craniofacial Biology; 3Department of Biochemistry and Molecular Genetics, University of Colorado, Anschutz Medical Campus, Aurora, CO.

PULMONARY VENO-OCCLUSIVE DISEASE, UNEXPECTED NUMBERS IN A RARE DISEASE: A CASE SERIES. Brett Begley1*, O. Agbaji1, Reda Girgis2, 1Spectrum Health, Internal Medicine Residency, Grand Rapids, MI; 2Director of Pulmonary Hypertension and Lung Transplantation, Fred and Lena Meijer Heart Center, Grand Rapids, MI.

FEMALE RATS DEVELOP CONSISTENTLY SEVERE PULMONARY HYPERTENSION FOLLOWING PNEUMONECTOMY AND LOW DOSE MONOCROTALINE. R. James White*, D. Haight, D.J. Lachant, University of Rochester, Rochester, NY.

DYSREGULATION OF Nrf2/ARE REGULATED ANTIOXIDANT GENES AND THE CELLULAR REDOX ENVIRONMENT BY THE HIV TRANSACTIVATOR OF TRANSCRIPTION: IMPLICATIONS FOR HIV-ASSOCIATED PULMONARY ARTIERAL HYPERTENSION. Ari Simenauer*, B. Assefa, J. Rios-Ochoa, A. Cota-Gomez, University of Colorado Anschutz Medical Campus, Aurora, CO.


POSTER VIEWING – Wine and Cheese Reception
Friday, June 7, 2019
5:00-7:00 PM


POSTERS

THE BROWN ALGAE POLYSACCHARIDE FUCOIDAN -P-SELECTIN AXIS FOR TREATMENT OF HYPOXIA-INDUCED PULMONARY HYPERTENSION. T. Novoyatleva1*, B. Kojonazarov1*, A. Owczarek1, S. Veeroju1, N. Rai1, I. Henneke1, M. Böhm1, F. Grimminger1, H.A. Ghofrani1, W. Seeger1,2, N. Weissmann1, Ralph T. Schermuly1*, 1Universities of Giessen and Marburg Lung Center (UGMLC), Excellence Cluster Cardio-Pulmonary System (ECCPS), Member of the German Center for Lung Research (DZL), Justus-Liebig-University Giessen, Giessen, Germany; 2Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany

TARGETING LOXL2 IN PULMONARY HYPERTENSION. Jochen Steppan1*, H. Wang1, Y. Nomura1, S. Jandu1, S. Melucci1, D. Bedja2, G. Zhu2, D.E Berkowitz1, L. Shimoda3, L. Santhanam1, Johns Hopkins University, School of Medicine, Departments of 1Aesthesiology and Critical Care Medicine, 2Cardiology, 3Pulmonary and Critical Care Medicine Baltimore, MD.

DISRUPTION OF ENDOTHELIAL-DERIVED ANGIOCRINE FACTOR SIGNALING PERTURBS THE DEVELOPMENT OF PULMONARY HYPERTENSION. Alexandra C. Racanelli1*, D. Chavez2, P. Guo3, A. Zhou1, Y. Zhu4, A.C. Borczuk5, B.-S. Ding2, A.M.K. Choi1, 1Division of Pulmonary Critical Care Medicine, Department of Medicine, New York Presbyterian Hospital-Weill Cornell Medicine, New York, NY; 2Fibrosis Research Center, Division of Pulmonary, Critical Care and Sleep Medicine, Icahn School of Medicine at Mount Sinai, New York, NY; 3Division of Regenerative Medicine, Department of Medicine, Weill Cornell Medicine, New York, NY; 4Institute of Systems Biomedicine, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China; 5Department of Pathology, New York Presbyterian Hospital-Weill Cornell Medicine, New York, NY.

RESISTIN PREDICTS DISEASE SEVERITY AND SURVIVAL IN PULMONARY ARTERIAL HYPERTENSION. Li Gao1*, J. Skinner2, E. Hunter2, R. Johns2, 1Division of Allergy & Clinical Immunology, Department of Medicine; 2Department of Anesthesia and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD

CARDIAC MAGNETIC RESONANCE IMAGING PREDICTS TREATMENT OUTCOMES IN PULMONARY HYPERTENSION PATIENTS. Arun Jose1*, J.M. Elwing2, R. O’Donnell3, 1University of Cincinnati, Cincinnati Ohio; 2University of Cincinnati, Cincinnati Ohio; 3University of Cincinnati, Cincinnati Ohio.

CORRELATING THE ORAL MICROBIOME WITH NITRATE METABOLISM IN PATIENTS WITH PH-HFPEF. Noel Britton*, MPH1,2,3, C. Koch1,3, A. Levine1,2, N. Helbling1, S. Shiva1, A. Fitch3 , R. Nettles3, B. Methé1,3, J. Lundberg4, M. Simon1, M.T. Gladwin1, A. Morris1,3, 1University of Pittsburgh School of Medicine and University of Pittsburgh Medical Center, Pittsburgh, PA; 2Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA; 3Center for Medicine and The Microbiome, University of Pittsburgh, Pittsburgh, PA; 4Department of Physiology and Pharmacology, Karolinska Institute, Stockholm.

NON-CANONICAL HIPPO-MST1/2 SUPPORTS PRO-PROLIFERATIVE/PRO-SURVIVAL VASCULAR SMOOTH MUSCLE PHENOTYPE AND ESTABLISHED PULMONARY HYPERTENSION VIA MODULATING AKT1 AND FOXO1. Tatiana Kudryashova1*, A. Ray1, A. Rode1, Y. Shen1, T. Avolio1, D. Goncharov1, Y. Zhao2, E. Goncharova1, 1Vascular Medicine Institute, Department of Medicine, University of Pittsburgh, Pittsburgh, PA; 2Department of Physiology and Cell Biology, The Ohio State University, Columbus, OH.

H3K27 MODIFICATIONS: MECHANISMS OF REPRESSION OF MIR-124 AND THERAPEUTIC IMPLICATION IN PULMONARY HYPERTENSION. Hui Zhang1*, A. Laux2, D. Wang1, A. Flockton1, C.-J. Hu2, K. Stenmark1, 1Cardiovascular Pulmonary Research Laboratories, Departments of Pediatrics and Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO; 2Department of Craniofacial Biology School of Dental Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO.

CAV1-SILENCED HUMAN PULMONARY ARTERY ENDOTHELIAL CELLS: HYPERPROLIFERATION ASSOCIATED WITH JAK/STAT AND PI3K/AKT ACTIVATION. Salina Gairhe*, K.S. Awad, E.J. Dougherty, G.A. Ferreyra, S. Wang, J.M. Elinoff , R.L. Danner, Critical Care Medicine Department, Clinical Center, National Institute of Health, Bethesda, MD.

FIBROBLAST GENERATED EXTRACELLULAR VESICLES INDUCES METABOLIC REPROGRAMMING IN BONE MARROW DERIVED MACROPHAGES. Sushil Kumar*, R. Balalsubramaniyan, M. L. Floren, S. Riddle, H. Zhang, M. Li, M. G. Frid, K. Hansen, K. R. Stenmark, University of Colorado Denver, Aurora, CO.

ANALYSIS OF NOVEL BIOMARKERS ASSOCIATED WITH THE DEVELOPMENT OF SCLERODERMA-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION. Akshay Muralidhar*, C. Meadows, C. Abbott, P. Senecal, A. Fischer, B.B. Graham, P. Hountras, D.B. Badesch, T.M. Bull, Pulmonary Sciences and Critical Care Medicine, University of Colorado, Aurora, CO.

A NOVEL MULTI-HARMONIC APPROACH TOWARDS CHARACTERIZING RIGHT VENTRICLE – PULMONARY ARTERY INTERACTION. Akshay Muralidhar1*, S. Hsu2, S. C. Mathai3, T. M. Bull1, R. J. Tedford4, K. S. Hunter5, 1Pulmonary Sciences and Critical Care Medicine, University of Colorado, Aurora, CO; 2Cardiology, Johns Hopkins University, Baltimore, MD; 3Pulmonary and Critical Care Medicine, John Hopkins School of Medicine, Baltimore, MD; 4Medicine/Cardiology, Medical University of South Carolina, Charleston, SC; 5Bioengineering, University of Colorado at Denver, Aurora, CO.

EVALUATING THE ROLE OF BMPER IN PULMONARY HYPERTENSION. Lavannya Pandit1*, M. Hua2, H. Karmouty-Quintana3, X. Pi2, 1Department of Medicine, Michael E. DeBakey Veterans Affairs Medical Center/Baylor College of Medicine(BCM); 2Department of Medicine, Baylor College of Medicine; 3University of Texas Health Science Center at Houston, TX.

NON-MUSCLE MYOSIN LIGHT CHAIN KINASE ACTIVATION INCREASES ENDOTHELIAL CELL PROLIFERATION AND IDENTIFIES A ROLE FOR CYTOSKELETAL REGULATION IN PULMONARY ARTERIAL HYPERTENSION. Dustin R. Fraidenburg*, M. Anis, R. Halstrom, N. Baig, S.M. Dudek, J.R. Jacobson, University of Illinois at Chicago, Chicago, IL.

ROLE OF PIONEER TRANSCRIPTION FACTORS IN THE PERSISTENT ACTIVATED PHENOTYPE OF PH VASCULAR CELLS. A. Laux1, H. Zhang2, K.R. Stenmark2, Cheng Jun Hu1*, 1Department of Craniofacial Biology School of Dental Medicine; 2Cardiovascular Pulmonary Research Laboratories, Division of Pulmonary Sciences and Critical Care Medicine, Division of Pediatrics-Critical Care, Departments of Medicine and Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO.

PERSONALIZED MEDICINE FOR PULMONARY HYPERTENSION - THE FUTURE. Gabriele Grunig1-3*, N. Durmus2, S. Pylawka3, 1Departments of Environmental Medicine; 2Medicine, NYU School of Medicine, New York, NY; 3Mirna Analytics, New York, NY.

IDENTIFYING PROCOAGULANT EXTRACELLULAR VESICLES IN PAH: A STEP TOWARDS PERSONALIZED MEDICINE. Daniel Lachant*, A. Light, D. Haight, R.J. White, University of Rochester Medical Center, Rochester, NY.

ENDOTHELIAL DYSFUNCTION IN COUPTF2 SILENCED CELLS. Edward J. Dougherty*, L.-Y. Chen, K.S. Awad, C.S. Curran, Y. Ding, J.M. Elinoff, A.F. Suffredini, R.L. Danner, Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD.

HYMECROMONE INHIBITS FIBROTIC DEPOSITION AND PULMONARY HYPERTENSION IN AN EXPERIMENTAL MODEL OF COMBINED PULMONARY FIBROSIS AND EMPHYSEMA (CPFE). S.D. Collum1, J.G. Molina1, A. Hanmandlu1, W. Bi1, M. Pedroza1, N.-Y. Chen1, T. Weng1, T. Mertens1, C. Wilson1, M.R. Blackburn1, S.S.K. Jyothula2, Harry Karmouty-Quintana1*, 1Department of Biochemistry and Molecular Biology; 2Department of Internal Medicine, McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX.

BASELINE CHARACTERISTICS FROM A PRE-SPECIFIED INTERIM ANALYSIS OF A PHASE IIB, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF SILDENAFIL ADDED TO PIRFENIDONE IN PATIENTS WITH ADVANCED IDIOPATHIC PULMONARY FIBROSIS AND RISK OF PULMONARY HYPERTENSION. J. Behr1, S.D. Nathan,2 S. Harari,3 W. Wuyts,4 N.M. Bishop,5 D.E. Bouros,6 K. Antoniou,7 J. Guiot,8 M. Kramer,9 K.-U. Kirchgaessler,10 M. Bengus,10 F. Gilberg,10 A.U. Wells11, 1Department of Internal Medicine V, LMU and Asklepios Fachkliniken Gauting, Comprehensive Pneumology Center, Munich, Germany; Member of the German Center for Lung Research; 2Inova Heart and Vascular Institute, Inova Fairfax Hospital, Falls Church, VA; 3U.O. di Pneumologia e Terapia Semi-Intensiva Respiratoria, Servizio di Fisiopatologia Respiratoriea ed Emodinamica Polmonare, Ospedale San Giuseppe, MultiMedica IRCCS, Milan Italy; 4Department of Pulmonary Medicine, Unit for Interstitial Lung Diseases, University of Leuven, Leuven, Belgium; 5Department of Pulmonary Medicine, Unit for Interstitial Lung Diseases, Ege University Hospital, Izmir, Turkey; 6National and Kapodistrian University of Athens, Athens, Greece; 7Department of Thoracic Medicine, University of Crete, Heraklion, Crete, Greece; 8Respiratory Department and GIGA-13 Research Unit, CHU Liège, Liège, Belgium; 9Pulmonary Institute Rabin Medical Center, Petah Tikva, Israel; 10F. Hoffmann-La Roche Ltd., Basel, Switzerland; 11Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK. (Presented by John L. Stauffer, M.D., Genentech/Roche).


​​


Conference Program Learning Objectives

The overarching objectives of the Thomas L. Petty Aspen Lung Conference are to:

  1.  To provide an international forum for leading basic, translational, and clinical researchers to exchange ideas regarding fundamental concepts in the pathogenesis and treatment of PH

  2. To stimulate interactions between the fields of pulmonology, cardiology and oncology with the goal of identifying emerging, shared interests that will lead to more efficient and productive research. 

  3. To advance our understanding of clinical and molecular PH pathobiology in order to translate preclinical findings to more effective, personalized therapies. 

  4. To challenge and thereby stimulate the scientific interests of trainees, attracting a new generation of junior investigators into the field of PH pathobiology.

     ​


Sponsored by the University of Colorado School of Medicine

Office of Continuing Medical Education​